Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Depemokimab - GSK

Next Previous
Drug Profile

Depemokimab - GSK

Alternative Names: AQ-82742999; Exdensur; GSK 294; GSK-3511294; GSK’294

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Asthma; Rhinosinusitis
  • Phase III Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Hypereosinophilic syndrome

Most Recent Events

  • 28 Jan 2026 GlaxoSmithKline completes phase-III Extension trial in Asthma (Adjunctive treatment, In adolescents, In adults, In children, In the elderly) in US, Japan, Australia, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, Taiwan and United Kingdom (Injection) (NCT05243680)
  • 06 Jan 2026 Registered for Asthma (Treatment-resistant) in Japan (SC)
  • 06 Jan 2026 Registered for Rhinosinusitis (Treatment-resistant) in Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top